Stockreport

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy [Yahoo! Finance]

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF - Mean sustained reductions in C3 of =87%, AH50 of =76%, Wieslab AP of =89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% b [Read more]